eFFECTOR Therapeutics Inc (OTCPK:EFTR)
$ 0.05168 -0.00852 (-14.15%) Market Cap: 244,000.00 Enterprise Value: -4.85 Mil PE Ratio: 0 PB Ratio: 0.25 GF Score: 0/100

eFFECTOR Therapeutics Inc at Credit Suisse Healthcare Conference Transcript

Nov 08, 2022 / 10:00PM GMT
Release Date Price: $12.35 (+0.80%)
Judah Frommer
Credit Suisse - Analyst

Good afternoon, everyone. I'm Judah Frommer. I'm one of the SMID-cap biotech analysts here at Credit Suisse. And for this session, we're very happy to have the team from eFFECTOR here: Steve, Mike, and Doug.

So maybe if we just jump right in. We thought we could start with a background question on the platform and the origin story for -- how did you land on the eIF4F translation complex? And how should we think about the optionality available for potential therapeutic mechanisms?

Questions & Answers

Steve Worland
eFFECTOR Therapeutics, Inc. - President & CEO

Yeah. Thanks, Judah. Thanks for the invitation. It's great to be here. I mean, I'll start with that. And then -- a lot of other people join in.

So I think the idea with the translational complex was, one, recognizing where it sits in cell signaling. So it's downstream of the RAS and the PI3K pathways, and it's actually a point of convergence of those two pathways, one of the very early points in signaling where the two pathways

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot